A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | MicrobiomeTrials← Back to trialsNCT03526835
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2018-05-02Est. Completion: 2028-05
Enrollment target: 560 participants Locations- UCSD, La Jolla, California, United States
- USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
- Sharp Healthcare, San Diego, California, United States
- Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States
- Florida Cancer Specialists, Fort Myers, Florida, United States
- University of Florida, Gainesville, Florida, United States
- Sarah Cannon Research Institute (Lake Nona), Orlando, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Massachusetts General Hospital - Dana Farber, Boston, Massachusetts, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- SSM Health Saint Louis University Hospital, St Louis, Missouri, United States
- Washington University School of Medicine at St Louis, St Louis, Missouri, United States
- Cayuga Medical Center, Ithaca, New York, United States
- Mt. Sinai, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Hematology-Oncology Associates of Central New York, Syracuse, New York, United States
Other microbiome trials you might be interested in
Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerHR+/HER2- Ductal and Lobular Breast CancerTriple Negative Breast CancerColorectal Cancer
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS…
Birmingham, United StatesEst. completion Jan 15, 2031
MelanomaGliomaThyroid CancerNon-Small Cell Lung Cancer
Cleveland Clinic, Cleveland, Ohio, United StatesOhio State University, Columbus, Ohio, United StatesTaylor Cancer Research Center, Maumee, Ohio, United StatesSSM OKC Hightower Clinical, Oklahoma City, Oklahoma, United StatesUniversity of Pennsylvania, Philadelphia, Pennsylvania, United StatesThe University Of Tennessee Health Science Center, Memphis, Tennessee, United StatesSarah Cannon Research Institute, Nashville, Tennessee, United StatesTexas Oncology, Dallas, Texas, United StatesOncology Consultants, Houston, Texas, United StatesTexas Oncology, Tyler, Texas, United StatesUtah Cancer Specialists, Salt Lake City, Utah, United StatesUniversity of Utah Health Huntsman Cancer Hospital, Salt Lake City, Utah, United StatesOncology & Hematology Associates of Southwest Virginia, Roanoke, Virginia, United StatesGeorgetown University Medical Center, Georgetown, Washington, United StatesCancer Care Northwest, Spokane, Washington, United StatesCliniques universitaires Saint-Luc, Brussels, BelgiumInstitut Jules Bordet, Brussels, BelgiumUZ Gent, Ghent, BelgiumChu Ucl Namur Site De Sainte-Elisabeth, Namur, BelgiumHopital Saint Andre, CHU Bordeaux, Bordeaux, FranceCentre Leon Berard, Lyon, FranceHopital La Timone, Marseille, FranceInstitut Régional du Cancer de Montpellier, Montpellier, FranceCentre Antoine Lacassagne, Nice, FranceInstitut Curie, Paris, FranceInstitut Gustave Roussy, Paris, FranceCentre Henri Becquerel, Rouen, FranceASST Grande Ospedale Metropolitano Niguarda, Milan, ItalyNKI - Antoni van Leeuwenhoek, Amsterdam, NetherlandsUMC Radboud, Nijmegen, NetherlandsUMC Utrecht, Utrecht, NetherlandsVall d'Hebron, Barcelona, SpainHospital 12 de Octubre, Madrid, SpainClinica Universidad de Navarra, Pamplona, SpainHospital Universitario de Navarra, Pamplona, SpainInstituto Valenciano de Oncologia, Valencia, SpainCambridge University Hospitals NHS Foundation Trust, Cambridge, United KingdomSarah Cannon Research Institute, London, United KingdomMalignant Neoplasms
Brain Neoplasms
Advanced or Metastatic Solid Tumors
HGG
LGG
Low Grade Glioma
High Grade Glioma
Differentiated Thyroid Cancer
NSCLC (Non-small Cell Lung Cancer)
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in co…
Birmingham, United StatesEst. completion Aug 2, 2027
Bladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed AdenocarcinomaBladder Neuroendocrine CarcinomaBladder Small Cell Neuroendocrine CarcinomaBladder Squamous Cell CarcinomaChromophobe Renal Cell CarcinomaCollecting Duct CarcinomaInvasive Bladder Giant Cell Urothelial CarcinomaInvasive Bladder Lymphoepithelioma-Like CarcinomaInvasive Bladder Nested Urothelial CarcinomaInvasive Bladder Plasmacytoid Urothelial CarcinomaInvasive Bladder Sarcomatoid Urothelial CarcinomaInvasive Bladder Urothelial CarcinomaKidney Medullary CarcinomaLarge Cell Neuroendocrine CarcinomaMalignant Testicular Leydig Cell TumorMalignant Testicular Sertoli Cell TumorMetastatic Bladder CarcinomaMetastatic Bladder Clear Cell (Glycogen-Rich) Urothelial CarcinomaMetastatic Bladder Giant Cell Urothelial CarcinomaMetastatic Bladder Large Cell Neuroendocrine CarcinomaMetastatic Bladder Lipid-Rich Urothelial CarcinomaMetastatic Bladder Micropapillary Urothelial CarcinomaMetastatic Bladder Plasmacytoid Urothelial CarcinomaMetastatic Bladder Sarcomatoid Urothelial CarcinomaMetastatic Bladder Small Cell Neuroendocrine CarcinomaMetastatic Bladder Squamous Cell CarcinomaMetastatic Chromophobe Renal Cell CarcinomaMetastatic Kidney Medullary CarcinomaMetastatic Malignant Genitourinary System NeoplasmMetastatic Papillary Renal Cell CarcinomaMetastatic Penile CarcinomaMetastatic Prostate Small Cell Neuroendocrine CarcinomaMetastatic Sarcomatoid Renal Cell CarcinomaMetastatic Urethral CarcinomaPapillary Renal Cell CarcinomaSarcomatoid Renal Cell CarcinomaStage IV Bladder Cancer AJCC v8Stage IV Penile Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Urethral Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Urachal AdenocarcinomaUrethral Clear Cell Adenocarcinoma
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patient…
Birmingham, United StatesEst. completion Feb 28, 2027